After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
BEAM belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Beam Therapeutics Inc is $2.13B. A total of 0.77 million shares were traded on the day, compared to an average of 1.19M shares.
In the most recent transaction, Evans John M. sold 30,000 shares of BEAM for 26.75 per share on Jan 30 ’25. After the transaction, the CEO now owns 908,659 company shares. In a previous transaction on Jan 30 ’25, JOHN M EVANS bought 30,000 shares at 26.75 per share.
Among the insiders who sold shares, Bellon Christine disposed of 1,241 shares on Jan 02 ’25 at a per-share price of $24.68. This resulted in the Chief Legal Officer holding 102,968 shares of BEAM after the transaction. In another insider transaction, Cavanagh Bethany J sold 1,117 shares at $24.68 per share on Jan 02 ’25. Company shares held by the SVP, Finance and Treasurer now total 43,814.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, BEAM has a high of $49.50 and a low of $20.84.
As of this writing, BEAM has an earnings estimate of -$1.22 per share for the current quarter. EPS was calculated based on a consensus of 16.0 estimates, with a high estimate of -$0.88 per share and a lower estimate of -$1.59.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. BEAM’s latest balance sheet shows that the firm has $965.65M in Cash & Short Term Investments as of fiscal 2021. There were $142.35M in debt and $213.44M in liabilities at the time. Its Book Value Per Share was $9.58, while its Total Shareholder’s Equity was $826.74M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BEAM is Buy with a score of 4.38.
